PSG: Specialty Drug Trend Continues Upward.

The article focuses on the continued rise in specialty drug spending, driven by higher costs per claim and increased patient usage. Topics include the slow uptake of Humira biosimilars, the shift of high-cost specialty drugs from medical to pharmacy benefits, and the growing impact of GLP-1 drugs. The report also highlights a slow adoption of Humira biosimilars, a shift in drug coverage from medical to pharmacy benefits.